Dimerix has entered into a Development and License Agreement for Japan

Dimerix Limited (ASX: DXB) and FUSO Pharmaceutical Industries Limited have entered into an exclusive development and license agreement for Dimerix's Phase 3 drug candidate DMX-200. This drug is used to treat focal segmental glomerulosclerosis kidney disease in Japan. While Dimerix retains rights outside licensed territories, FUSO will handle development costs, regulatory submissions, and sales in Japan. Under the agreement, Dimerix will receive an upfront payment of ¥300 million within 40 days, ¥400 million upon initiating clinical trial sites in Q1 2025, and up to ¥9.8 billion in milestone payments. Dimerix will also earn 15-20% royalties on net sales in Japan.

The global Phase 3 ACTION3 study for DMX-200, funded and executed by Dimerix outside Japan, will align with FUSO's efforts through a Joint Steering Committee. Data from FUSO's activities will support Dimerix's global commercialization strategies. The agreement includes standard terms and termination clauses, while Dimerix explores additional licensing opportunities in the USA and Mainland China.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com